Novo Nordisk Shares Drop 3% on CagriSema Readout and Wegovy Sales Shortfall
NVO•Novo Nordisk shares fell 3% after ADA conference presentations offered incremental pipeline updates rather than near-term catalysts. New REIMAGINE-1 data showed half of patients maintained HbA1c at or below 6.5% twelve weeks post-CagriSema, while US Wegovy pill prescriptions hit 3 million with an estimated DKK605m sales shortfall for fiscal 2026.
1. Share Decline Reflects Incremental Pipeline Updates
Novo Nordisk shares fell 3% after ADA conference presentations delivered encouraging but non-disruptive clinical data and commercial metrics, signaling limited near-term catalysts for investors.
2. CagriSema REIMAGINE-1 Data Highlights Durability
In REIMAGINE-1, approximately 50% of Type 2 diabetes patients maintained HbA1c ≤6.5% twelve weeks after stopping CagriSema therapy, underscoring potential disease-modifying effects ahead of a late-2027 regulatory filing.
3. Wegovy Pill Prescriptions and Sales Outlook
US Wegovy pill prescriptions reached 3 million in early June, but updated estimates project DKK13,684 million in fiscal 2026 sales—about 5% below current forecasts—translating to less than a 1% impact on overall revenue.
4. Focus Shifts to Upcoming Milestones and Competition
With the extended timeline to CagriSema commercialization, investor attention is likely to center on upcoming cardiovascular outcomes results, other clinical readouts, and competitive dynamics in diabetes and obesity markets.
